A phase IIb Clinical Trial Assessing EXN407 New Eyedrop for Alleviating Retinopathy in Diabetic Macular Oedema
Latest Information Update: 07 Mar 2024
At a glance
- Drugs EXN 407 (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms CLEAR-DM
Most Recent Events
- 07 Mar 2024 New trial record
- 05 Mar 2024 According to Exonate media release, Exonate is now planning to progress EXN407 to the CLEAR-DM (Clinical Evaluation of a New Eyedrop for Alleviating Retinopathy in Diabetic Macular Oedema) Phase IIb clinical trial.